Literature DB >> 9437561

First week drug concentrations in women with levonorgestrel rod or Norplant capsule implants.

I Sivin1, P Lähteenmäki, D R Mishell, F Alvarez, S Diaz, S Ranta, C Grozinger, M Lacarra, V Brache, M Pavez, H Nash, J Stern.   

Abstract

Forty-two healthy women volunteered to have blood samples drawn at 2, 4, 8, 24, 48, and 168 h (7 days) following placement of levonorgestrel-releasing rod (LNG rod) or of Norplant capsule implants to permit measurement of drug concentrations. Three clinics recruited 10 women each, half of whom used each type of implant. Twelve additional subjects were later enrolled at one site to provide greater detail for the capsule implants. Throughout the week, women with Norplant implants had apparently higher mean drug concentrations than did women with LNG rod implants, but the differences were significant only in the first 48 h after placement (p < 0.05). Maximum levels for capsule implants were found at the 24-h sample (mean, 1358 to 1474 pg/mL) and for the LNG rod implants at 48 h (772 pg/mL). Body weight was negatively correlated with levonorgestrel concentrations at all times (p < 0.05). For several sampling times, differences between clinics in mean concentrations were statistically significant after weight adjustment. Despite differences by implant type, weight, or clinic location, drug concentrations compatible with contraceptive effect were attained within 24 h in users of LNG rod or of Norplant implants, insofar as all women had levonorgestrel concentrations above 250 pg/mL at the 24-h sample.

Entities:  

Keywords:  Americas; Biology; Body Weight--women; Caribbean; Chile; Clinical Research; Contraception; Contraceptive Agents, Female--pharmacodynamics; Contraceptive Agents, Progestin--pharmacodynamics; Contraceptive Agents--pharmacodynamics; Contraceptive Effectiveness; Contraceptive Implants; Contraceptive Methods; Demographic Factors; Developed Countries; Developing Countries; Dominican Republic; Family Planning; Latin America; Levonorgestrel--pharmacodynamics; North America; Northern America; Physiology; Population; Population Dynamics; Research Methodology; Research Report; South America; Time Factors; United States

Mesh:

Substances:

Year:  1997        PMID: 9437561     DOI: 10.1016/s0010-7824(97)00153-4

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  10 in total

1.  Ulnar nerve ligation after removal of Norplant: a case report.

Authors:  Joshua M Adkinson; Jay S Talsania
Journal:  Hand (N Y)       Date:  2013-03

2.  Development, validation and utilization of a highly sensitive LC-MS/MS method for quantification of levonorgestrel released from a subdermal implant in human plasma.

Authors:  Lauren R Cirrincione; Sujan Dilly Penchala; Kimberly K Scarsi; Anthony T Podany; Lee C Winchester; David J Back; Saye H Khoo; Courtney V Fletcher; Marco Siccardi; Laura J Else
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2018-03-12       Impact factor: 3.205

3.  In vitro and in vivo evaluations of biodegradable implants for hormone replacement therapy: effect of system design and PK-PD relationship.

Authors:  S Lin; P Y Chao; Y W Chien; S Sayani; S Kuma; M Mason; T Wes; A Yang; D Monkhouse
Journal:  AAPS PharmSciTech       Date:  2001-09-21       Impact factor: 3.246

Review 4.  Levonorgestrel subdermal implants. A review of contraceptive efficacy and acceptability.

Authors:  A J Coukell; J A Balfour
Journal:  Drugs       Date:  1998-06       Impact factor: 9.546

5.  The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or Nevirapine.

Authors:  M Neary; M Lamorde; A Olagunju; K M Darin; C Merry; P Byakika-Kibwika; D J Back; M Siccardi; A Owen; K K Scarsi
Journal:  Clin Pharmacol Ther       Date:  2017-05-30       Impact factor: 6.875

6.  Mating skew in Barbary macaque males: the role of female mating synchrony, female behavior, and male-male coalitions.

Authors:  Annie Bissonnette; Nicole Bischofberger; Carel P van Schaik
Journal:  Behav Ecol Sociobiol       Date:  2010-07-23       Impact factor: 2.980

Review 7.  Pharmacokinetics, metabolism and serum concentrations of progestins used in contraception.

Authors:  Alexis J Bick; Renate Louw-du Toit; Salndave B Skosana; Donita Africander; Janet P Hapgood
Journal:  Pharmacol Ther       Date:  2020-12-13       Impact factor: 13.400

8.  Impact of one-rod levonorgestrel implant on the blood chemistry profile.

Authors:  Eka R Gunardi; Raymond Surya; Inayah Syafitri; Yogi Pasidri
Journal:  Sci Rep       Date:  2021-10-11       Impact factor: 4.379

9.  Levonorgestrel Microneedle Array Patch for Sustained Release Contraception: Formulation, Optimization and In Vivo Characterization.

Authors:  Amarjitsing Rajput; Riyaz Ali M Osmani; Achyut Khire; Sanket Jaiswal; Rinti Banerjee
Journal:  Molecules       Date:  2022-04-06       Impact factor: 4.411

10.  Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks.

Authors:  Kimberly K Scarsi; Kristin M Darin; Shadia Nakalema; David J Back; Pauline Byakika-Kibwika; Laura J Else; Sujan Dilly Penchala; Allan Buzibye; Susan E Cohn; Concepta Merry; Mohammed Lamorde
Journal:  Clin Infect Dis       Date:  2015-12-08       Impact factor: 9.079

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.